Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ADX-629

Other · developed by Aldeyra Therapeutics

Phase 2 Most advanced trial (none active)

ALDX Developer

2 Registered trials

What is ADX-629?

ADX-629 is a drug studied twice daily at doses of 125 mg and 250 mg in trials in atopic dermatitis and alcohol hepatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Dermatology, Gastroenterology
Developer: Aldeyra Therapeutics, Inc. (ALDX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06685692	Phase 2	Alcohol Hepatitis	Completed	ALDX
NCT05717920	Phase 2	Atopic Dermatitis	Completed	ALDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alcohol HepatitisAtopic Dermatitis

More from Aldeyra Therapeutics

NS2 Phase 2 Reproxalap Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALDX page.

Follow ALDX, the company behind ADX-629

See ALDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALDX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z